Half-Life of Tenecteplase (TNK-tPA)
The terminal plasma half-life of tenecteplase is 90 to 130 minutes 1.
Pharmacokinetic Profile
Tenecteplase exhibits biphasic elimination from plasma after IV bolus administration 1:
- Initial disposition phase half-life: 17-24 minutes (some studies report 11-20 minutes) 2, 3
- Terminal phase half-life: 90-130 minutes (range 65-132 minutes in some studies) 1, 2
This biphasic pattern means the drug is cleared rapidly in the first phase, followed by a slower terminal elimination phase.
Clinical Significance
The prolonged half-life of tenecteplase compared to alteplase (tPA) is a key pharmacological advantage that enables:
- Single bolus administration over 5-10 seconds 1, 4
- No need for the 90-minute infusion required with alteplase
- Simplified dosing in emergency settings
The half-life of tenecteplase is approximately 6-fold longer than alteplase (22 minutes vs 3.5 minutes for the initial phase) 2. This was achieved through specific genetic modifications that also conferred 15-fold higher fibrin specificity and 80-fold reduced binding to plasminogen activator inhibitor-1 (PAI-1) 2.
Additional Pharmacokinetic Parameters
For context 1:
- Plasma clearance: 99-119 mL/min (dose range 30-50 mg)
- Volume of distribution: 4.22-5.43 L (central compartment), approximating plasma volume
- Steady-state volume: 6.12-8.01 L, suggesting limited extravascular distribution
- Metabolism: Primarily hepatic clearance
Body weight influences clearance (explaining 19% of variability), which is why tenecteplase is dosed in a weight-tiered fashion 1.